CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

$17.06  -0.84 (-4.69%)
As of 04/09/2021 15:59:53 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/18/2018
Outstanding shares:  33,028,876
Average volume:  168,011
Market cap:   $563,802,913
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    22663K107
ISIN:        US22663K1079
Sedol:      BDD19F8
Valuation   (See tab for details)
PE ratio:   -32.48
PB ratio:   3.19
PS ratio:   0.00
Return on equity:   -30.89%
Net income %:   -73,480.28%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy